<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264381</url>
  </required_header>
  <id_info>
    <org_study_id>10341</org_study_id>
    <secondary_id>ORA-20030415</secondary_id>
    <nct_id>NCT00264381</nct_id>
  </id_info>
  <brief_title>Management of Superficial Thrombophlebitis</brief_title>
  <official_title>Management of Superficial Thrombophlebitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium)
      subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three
      times daily for 7 days for the treatment of superficial thrombophlebitis (STP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Superficial thrombophlebitis is a common problem and is thought to affect up to 20% of
      patients with varicose veins. In the absence of treatment, STP may cause its greatest
      morbidity with extension of thrombus into the deep venous system and resultant risk of
      pulmonary embolism.

      Current standard therapy for STP consists of local heat, elevation of the extremity, and
      non-steroidal anti-inflammatory medication. However, no study to date has adequately
      evaluated the effectiveness of this therapy despite persistence and recurrence of symptoms of
      STP in many patients.

      The purpose of this study is to document the outcome of patients with objectively documented
      STP who are treated with NSAID therapy (standard care) verses those treated with
      low-molecular weight heparin (dalteparin sodium) according to a pre-defined treatment
      regimen.

      All patients with documented upper or lower STP will be screened. Each will have a complete
      baseline and risk factor assessment.

      All patients will be randomized in one of two treatment groups:

      (a) Experimental group who will receive Fragmin (dalteparin)fixed dose subcutaneously daily
      for 7 days or (b) Control group who will receive ibuprofen 800mg given orally three times
      daily for 7 days. All patients will receive study drug for a period of 1-2 weeks with
      reassessment of STP by ultrasound.

      All patients will participate for a period of 3 months with follow up visits at 7-9, and
      14-16 day, and 1,3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombosis Progression and Venous Thromboembolism (VTE)</measure>
    <time_frame>Day 14</time_frame>
    <description>Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombosis Progression or Venous Thromboembolism (VTE) at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Symptomatic thrombosis extension (DVT) or pulmonary embolism at 3 months documented by radiologic testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major and Minor Bleeding Secondary to Dalteparin and Ibuprofen Treatment During the 3 Month Follow up.</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with bleeding events related to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 14 in Pain Assessment</measure>
    <time_frame>Day 1, Day 14</time_frame>
    <description>Change in pain at day 14 as measured by 11-point Box Pain Scale, 0 being the least amount of pain, and 10 the most amount of pain</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Superficial Thrombophlebitis</condition>
  <condition>Upper Extremity Superficial Thrombophlebitis</condition>
  <condition>Lower Extremity Superficial Thrombophlebitis</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 800mg tid X 7 days + additional 7 days determined by protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin sodium injection</intervention_name>
    <description>Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed upper or lower extremity superficial thrombophlebitis by
             ultrasound imaging

        Exclusion Criteria:

          -  Active, clinically significant bleeding

          -  Known hypersensitivity to NSAIDS, heparin or derivatives

          -  Currently pregnant or &lt; 1 week post-partum

          -  Acquired bleeding diathesis

          -  Known inherited bleeding disorder

          -  Renal failure

          -  Extremes of weight

          -  unable to return for repeat diagnostic testing or follow-up visit

          -  Concurrent deep-vein thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Rathbun, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma Medicine/Cardiovascular Section</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rathbun SW, Aston CE, Whitsett TL. A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis. J Thromb Haemost. 2012 May;10(5):833-9. doi: 10.1111/j.1538-7836.2012.04669.x.</citation>
    <PMID>22360152</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2005</study_first_submitted>
  <study_first_submitted_qc>December 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <results_first_submitted>November 14, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2013</results_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial Thrombophlebitis</keyword>
  <keyword>STP</keyword>
  <keyword>Fragmin</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Superficial Thrombus</keyword>
  <keyword>Superficial Phlebitis</keyword>
  <keyword>phlebitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombophlebitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive patients, inpatient and outpatient, with ultrasound confirmed superficial thrombophlebitis of the upper or lower extremity</recruitment_details>
      <pre_assignment_details>Exclusion criteria: receiving anticoagulant therapy for more than 24 hours, concurrent DVT, active bleeding, hypersensitivity to NSAIDS, pregnant or &lt;1 week post-partum, history of bleeding gastric ulcers, hemorrhagic CVA in last year, platelet count&lt;100K, bleeding disorder, serum creatine &gt; 2mg/dl, BP &gt; 180/110, weight &lt;40kg or &gt;135kg</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibuprofen 800 mg Tid</title>
          <description>Ibuprofen 800mg orally tid for 7 days + one placebo injection daily for 7 days
+ additional 7 days of same therapy based on result of ultrasound at day 7</description>
        </group>
        <group group_id="P2">
          <title>Dalteparin 200 U/kg Then 10,000 U Daily</title>
          <description>Dalteparin 200 units/kg subcutaneously injection on day one then 10,000 units daily for 6 additional doses + placebo orally for 7 days
+ additional 7 days of same therapy based on results of ultrasound at day 7</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibuprofen 800 mg Tid</title>
          <description>Ibuprofen 800mg orally tid for 7 days + one placebo injection daily for 7 days
+ additional 7 days of same therapy based on result of ultrasound at day 7</description>
        </group>
        <group group_id="B2">
          <title>Dalteparin 200 U/kg Then 10,000 U Daily</title>
          <description>Dalteparin 200 units/kg subcutaneously injection on day one then 10,000 units daily for 6 additional doses + placebo orally for 7 days
+ additional 7 days of same therapy based on results of ultrasound at day 7</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="19" upper_limit="85"/>
                    <measurement group_id="B2" value="51" lower_limit="28" upper_limit="88"/>
                    <measurement group_id="B3" value="51" lower_limit="19" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Major and Minor Bleeding Secondary to Dalteparin and Ibuprofen Treatment During the 3 Month Follow up.</title>
        <description>Number of participants with bleeding events related to treatment</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen 800 mg Tid</title>
            <description>Ibuprofen 800mg orally tid for 7 days + one placebo injection daily for 7 days
+ additional 7 days of same therapy based on result of ultrasound at day 7</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin 200 U/kg Then 10,000 U Daily</title>
            <description>Dalteparin 200 units/kg subcutaneously injection on day one then 10,000 units daily for 6 additional doses + placebo orally for 7 days
+ additional 7 days of same therapy based on results of ultrasound at day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Major and Minor Bleeding Secondary to Dalteparin and Ibuprofen Treatment During the 3 Month Follow up.</title>
          <description>Number of participants with bleeding events related to treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Thrombosis Progression and Venous Thromboembolism (VTE)</title>
        <description>Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing</description>
        <time_frame>Day 14</time_frame>
        <population>Total number available for follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen 800 mg Tid</title>
            <description>Ibuprofen 800mg orally tid for 7 days + one placebo injection daily for 7 days
+ additional 7 days of same therapy based on result of ultrasound at day 7</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin 200 U/kg Then 10,000 U Daily</title>
            <description>Dalteparin 200 units/kg subcutaneously injection on day one then 10,000 units daily for 6 additional doses + placebo orally for 7 days
+ additional 7 days of same therapy based on results of ultrasound at day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombosis Progression and Venous Thromboembolism (VTE)</title>
          <description>Thrombosis progression and deep vein thrombosis at day 14 by ultrasound testing</description>
          <population>Total number available for follow up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Thrombosis progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VTE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Thrombosis Progression or Venous Thromboembolism (VTE) at 3 Months</title>
        <description>Symptomatic thrombosis extension (DVT) or pulmonary embolism at 3 months documented by radiologic testing.</description>
        <time_frame>3 months</time_frame>
        <population>Participants available for follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen 800 mg Tid</title>
            <description>Ibuprofen 800mg orally tid for 7 days + one placebo injection daily for 7 days
+ additional 7 days of same therapy based on result of ultrasound at day 7</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin 200 U/kg Then 10,000 U Daily</title>
            <description>Dalteparin 200 units/kg subcutaneously injection on day one then 10,000 units daily for 6 additional doses + placebo orally for 7 days
+ additional 7 days of same therapy based on results of ultrasound at day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombosis Progression or Venous Thromboembolism (VTE) at 3 Months</title>
          <description>Symptomatic thrombosis extension (DVT) or pulmonary embolism at 3 months documented by radiologic testing.</description>
          <population>Participants available for follow up</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Thrombosis progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VTE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 14 in Pain Assessment</title>
        <description>Change in pain at day 14 as measured by 11-point Box Pain Scale, 0 being the least amount of pain, and 10 the most amount of pain</description>
        <time_frame>Day 1, Day 14</time_frame>
        <population>Participants available at follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Ibuprofen 800 mg Tid</title>
            <description>Ibuprofen 800mg orally tid for 7 days + one placebo injection daily for 7 days
+ additional 7 days of same therapy based on result of ultrasound at day 7</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin 200 U/kg Then 10,000 U Daily</title>
            <description>Dalteparin 200 units/kg subcutaneously injection on day one then 10,000 units daily for 6 additional doses + placebo orally for 7 days
+ additional 7 days of same therapy based on results of ultrasound at day 7</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 14 in Pain Assessment</title>
          <description>Change in pain at day 14 as measured by 11-point Box Pain Scale, 0 being the least amount of pain, and 10 the most amount of pain</description>
          <population>Participants available at follow up</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="2.69"/>
                    <measurement group_id="O2" value="-2.23" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ibuprofen 800 mg Tid</title>
          <description>Ibuprofen 800mg orally tid for 7 days + one placebo injection daily for 7 days
+ additional 7 days of same therapy based on result of ultrasound at day 7</description>
        </group>
        <group group_id="E2">
          <title>Dalteparin 200 U/kg Then 10,000 U Daily</title>
          <description>Dalteparin 200 units/kg subcutaneously injection on day one then 10,000 units daily for 6 additional doses + placebo orally for 7 days
+ additional 7 days of same therapy based on results of ultrasound at day 7</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Major bleeding</sub_title>
                <description>Not related to study treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suman Rathbun MD,MS</name_or_title>
      <organization>University of Oklahoma Health Sciences Center</organization>
      <phone>405271-4742 ext 44773</phone>
      <email>suman-rathbun@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

